NCT07654140 SAL-0140 Resistant Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07654140—A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07654140 is a hot trial to watch
Resistant Hypertension is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07654140 is notable because it tests SAL-0140 in a Phase 2 design with The baseline change in mean seated systolic blood pressure (msSBP) as a primary decision variable. The wider PatSnap topic query returned 84 trial records and 63 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07654140 |
| Official title | A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension |
| Phase / status | Phase 2 / Recruiting |
| Intervention | SAL-0140 |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Geography | China |
| Enrollment | 252 |
| Primary endpoint | The baseline change in mean seated systolic blood pressure (msSBP) |
| Endpoint time frame | at week 12 |
| Primary completion | 2027-03-01 |
| Study completion | 2027-07-31 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—The baseline change in mean seated systolic blood pressure (msSBP)—determines what uncertainty this study can resolve. The reported time frame is at week 12. Enrollment of 252 participants and geography in China shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial (Phase 3): AE = 37.0 % ; AE = 52.0 % .
- RETRACTED: Effects of different antihypertensive drug classes on central and ambulatory blood pressure in resistant hypertension: A randomized clinical trial (Phase 4): DBP = 77.33 mmHg ; DBP = 78.11 mmHg .
- Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial (Phase 3): SBP(average 24-hour) = -2.6 mmHg (95%CI, -4.7 to -0.4) Met; SBP(average 24-hour) = -16.6 mmHg (95%CI, -18.8 to -14.3) Met.
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: SAL-0140 (Phase 2; Aldosterone).
Company & Deal Intelligence context: Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) — http://www.salubris.com.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07654140 is a focused lens on Resistant Hypertension development. Its value will be determined by whether SAL-0140 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
